Singh, Ajay K.Ajay K.SinghBlackorby, AllisonAllisonBlackorbyCizman, BorutBorutCizmanCarroll, KevinKevinCarrollCobitz, Alexander R.Alexander R.CobitzDavies, RichRichDaviesJha, VivekanandVivekanandJhaJohansen, Kirsten L.Kirsten L.JohansenLopes, Renato D.Renato D.LopesKler, LataLataKlerMacdougall, Iain C.Iain C.MacdougallMcMurray, John J. V.John J. V.McMurrayMeadowcroft, Amy M.Amy M.MeadowcroftObrador, GregorioGregorioObradorPerkovic, VladoVladoPerkovicSolomon, ScottScottSolomonWanner, ChristophChristophWannerWaikar, Sushrut S.Sushrut S.WaikarWheeler, David C.David C.WheelerWiecek, AndrzejAndrzejWiecek2022-11-242022-11-242021https://scripta.up.edu.mx/handle/20.500.12552/218610.1093/ndt/gfab065Background: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: hemoglobin (Hb) efficacy and cardiovascular (CV) safety. Methods: We report the trial design, key demographic, clinical and laboratory findings, and baseline therapies of 2964 patients randomized in the open-label (sponsor-blinded) active-controlled, parallel-group, randomized ASCEND-D clinical trial. We also compare baseline characteristics of ASCEND-D patients with patients who are on dialysis (CKD G5D) enrolled in other large CV outcome trials (CVOTs) and in the most relevant registries. © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA-EDTA.enAnemiaBaseline dataDaprodustatDialysisRecombinant human erythropoietinResource Types::text::journal::journal article